Abstract The epothilones and their analogs constitute a novel class of antineoplastic agents, produced by the myxobacterium Sorangium cellulosum. These antimicrotubule agents act in a similar manner to taxanes, stabilizing microtubules and resulting in arrested tumor cell division and apoptosis. Unlike taxanes, however, epothilones and their analogs are macrolide antibiotics, with a distinct tubulin binding mode and reduced susceptibility to a range of common tumor resistance mechanisms that limit the eVectiveness of taxanes and anthracyclines. While natural epothilones A and B show potent antineoplastic activity in vitro, these eVects were not seen in preclinical in vivo models due to their poor metabolic stability and unfavorable pharmacokinetics. A range of epothilone analogs was synthesized, therefore, with the aim of identifying those with more favorable characteristics. Here, we describe the preclinical characterization and selection of ixabepilone, a semi-synthetic epothilone B analog, among many other epothilone analogs. Ixabepilone demonstrated superior preclinical characteristics, including high metabolic stability, low plasma protein binding and low susceptibility to multidrug resistance protein-mediated eZux, all of which were predictive of potent in vivo cell-killing activity. Ixabepilone also demonstrated in vivo antitumor activity in a range of human tumor models, several of which displayed resistance to commonly used agents such as anthracyclines and taxanes.
Introduction
Since the clinical antitumor activity of the taxanes was discovered in the 1990s, the rationale for using microtubulestabilizing agents in the treatment of cancer is undisputed [1] . Taxanes are clinically active against a wide range of tumor types, and play a key role in the treatment of both primary and metastatic breast cancer [2] . However, resistance to cytotoxic drugs (including taxanes) is common, and results in reduced response rates and ultimate disease progression in most patients with metastatic cancer [3] . While some tumors display intrinsic resistance to chemotherapeutic drugs, and thus show no response, others are initially responsive to chemotherapy, but subsequently develop acquired resistance. Both intrinsic and acquired resistance lead to a requirement for alternative treatment options [3] .
A major mechanism by which tumors display resistance to commonly used agents such as taxanes and anthracyclines is through overexpression of multidrug resistance (MDR) proteins including P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP)-1 [4] . Overexpression of these eZux pump proteins causes retention of sub-therapeutic concentrations of drug in tumor cells, which results in a lack of eYcacy. In some tumors that are intrinsically resistant to chemotherapy, expression of MDR proteins reXects the constitutive expression of these proteins by the tissues from which the tumors are derived (for example, liver and kidney). However, in tumors derived from tissue types that do not express MDR proteins physiologically, treatment with chemotherapy can induce expression of these proteins. This results in acquired resistance to the chemotherapy agent used, in addition to drugs of the same class and, on occasion, of diVerent classes [3] . In the case of the taxanes, at least one other mechanism of drug resistance is known to exist: the overexpression of the III-tubulin isoform in preference to the II isoform reduces the eYcacy of taxanes, as these drugs speciWcally target the II isoform [5] [6] [7] [8] .
In recent years, there has been a great deal of interest among the oncology community in targeted agents. It is now widely acknowledged that agents such as trastuzumab (which targets HER2 in breast cancer) and bevacizumab (which targets VEGF to inhibit angiogenesis in a range of solid tumors) have the potential beneWts of at least comparable eYcacy and reduced side-eVects compared with cytotoxic agents. However, targeted therapies are only eVective in subsets of patients with tumors expressing the target molecule, hence it is likely that cytotoxic agents will remain important in the treatment of cancer, either in combination with other agents [as seen clinically with paclitaxel in combination with bevacizumab in trials of non-small cell lung carcinoma (NSCLC)] or second-line to other therapies [9, 10] . There is, therefore, a pressing need for the development of novel antineoplastic agents that are able to overcome major mechanisms of tumor drug resistance.
Natural epothilones and their analogs are a novel class of antineoplastic agents, produced by the myxobacterium Sorangium cellulosum [11, 12] . Like the taxanes, epothilones promote tumor cell death by stabilizing microtubules and inducing apoptosis [13] . However, as macrolide antibiotics, the epothilones are structurally unrelated to taxanes and have a distinct tubulin-binding mode. Moreover, unlike taxanes and anthracyclines, epothilones have low susceptibility to multiple mechanisms of tumor cell resistance, including MDR, III-tubulin overexpression and -tubulin mutations [8, 14, 15] .
The potential for reduced susceptibility to common mechanisms of tumor resistance led to preclinical and clinical evaluation of natural epothilones A-F (Fig. 1a) , and a wide range of synthetic and semi-synthetic analogs of these agents. This review will describe the preclinical development and selection of a particular epothilone analog, BMS-247550 (ixabepilone), a semi-synthetic analog of natural epothilone B that has shown phase II clinical activity in a wide range of tumor types, including those heavily pretreated with, and/or resistant to, prior therapies [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Epothilones and their analogs: a novel class of antineoplastic agents
Epothilones are 16-member macrolides with unique antibacterial and antifungal activity. Preclinical experiments have shown that natural epothilones A and B have potent antineoplastic activity against a wide range of tumor cell lines in vitro [14, 27] . This is particularly true for epothilone B, which showed greater in vitro activity when compared with epothilone A [28, 29] . However, this promising in vitro activity of these natural epothilones did not translate into robust in vivo preclinical antitumor eYcacy [30] . This was due to the poor metabolic stability and unfavorable pharmacokinetic properties of natural epothilones seen in rodent models. Synthetic and semi-synthetic epothilone analogs were, therefore, developed, with the aim of yielding more favorable preclinical characteristics that would lead to improved in vivo activity [31, 32] . This was possible due to the fact that epothilones have a structure of only moderate complexity, and are amenable to total and semisynthesis. A range of semisynthetic analogs was developed and tested by Bristol-Myers Squibb in order to identify candidates with a superior eYcacy and safety proWle versus epothilone B. Of these, ixabepilone is an analog rationally designed for high in vivo eYcacy, good metabolic stability, low protein binding and increased water solubility. The lactone oxygen is replaced with nitrogen, resulting in the lactam compound (Fig. 1b) . SigniWcantly, this lactam ring is not susceptible to hydrolysis by esterases, conferring metabolic stability on ixabepilone. Because of its improved water solubility, ixabepilone has a reduced requirement in its formulation for the solubilizing agent cremophor, an agent that has been associated with hypersensitivity reaction in patients.
Preclinical evaluation of ixabepilone
In order to be of clinical value, an epothilone analog must: (1) be eYcacious, resulting in clinically meaningful responses at practical concentrations; (2) have an acceptable safety proWle; and (3) be readily available through scalable synthesis.
While the in vitro cytotoxicity/activity of the drug may give some indication of how potent the drug will be in vivo, this is not always the case (as seen for natural epothilones B and A). This is because many confounding factors exist in the in vivo environment that are not present in simple in vitro systems, resulting in unpredictable diVerences in eYcacy when a drug initially evaluated in vitro is tested in vivo. For example, even though a drug may have very potent in vitro activity, it will not be clinically eVective unless it is metabolically stable in vivo, allowing therapeutic concentrations to be maintained for the required time. Determination of metabolic stability during preclinical development is, therefore, of great importance. Minimal plasma protein binding is another important factor related to in vivo eYcacy. If plasma protein binding is too high, eVective concentrations of the drug will not be distributed to the target tumor tissues. Due to the clinical signiWcance of MDR in many current chemotherapy treatments, low susceptibility to MDR-mediated eZux is an important characteristic for a novel agent to possess. However, too low a susceptibility to MDR could lead to gastrointestinal toxicity, since gastrointestinal cells normally are protected from the toxic eVects of drugs through expression of P-gp. It is important, therefore, that a level of MDR susceptibility of a given drug allows eVective drug concentrations to be maintained within cells, while minimizing gastrointestinal toxicity.
In order to evaluate properties that may be predictive of clinical eYcacy, a range of preclinical characteristics was determined for 15 semi-synthetic epothilone analogs synthesized by Bristol-Myers Squibb, including ixabepilone. Results of these assays (with brief methodologies) are described below, and summarized in Table 1 .
Preclinical in vivo eYcacy
As a measure of antitumor eYcacy, log cell kill (LCK) was determined for the 15 epothilone analogs and compared with that for the natural epothilones, using the patientderived Pat-7 ovarian carcinoma model (established from an ovarian cancer patient who had acquired resistance to standard of care chemotherapy, including TAXOL and platinum). Tumor xenografts demonstrated overexpression of P-gp (MDR) and multidrug resistance related protein (MRP) [14] . Tumor fragments approximately 50 mg in size were implanted subcutaneously and animals treated with the natural epothilones or the analogs. Tumor response to treatment was determined as previously described [14] . Statistical evaluations of the data were performed using Gehan's generalized Wilcoxon test [33] . Table 1 ). Furthermore, the LCK for ixabepilone was signiWcantly higher than that for natural epothilone B (LCK = 0.4; Fig. 2 ; P < 0.0017), suggesting greater in vivo antitumor eYcacy for ixabepilone; this was reXected by a more rapid reduction in tumor weight following ixabepilone treatment compared with natural epothilone B.
In vitro evaluations of ixabepilone potency

In vitro cytotoxicity
Having determined this higher in vivo antitumor activity for ixabepilone versus natural epothilone B and most of the 14 other analogs, in vitro characteristics were compared to determine whether these were predictive of in vivo eYcacy. In vitro antitumor potency was assessed on the basis of IC 50 values against HCT-116 cells (HCT-116 is a non-P-gp expressing cell line chosen for this purpose in order to avoid susceptibility to MDR as a confounding factor). The IC 50 values for the 15 analogs ranged from 0.29 to 130 nM. Encouragingly, ixabepilone retained a very low IC 50 value (2.60 nM), suggesting high cytotoxicity of this analog. However, the IC 50 for ixabepilone was comparable to that of natural epothilone B (0.41 nM), and the IC 50 values did not correlate with in vivo eYcacy as measured by LCK (Pearson correlation r = 0.22; P = 0.37).
Tubulin polymerization
Although IC 50 is a valuable pharmacologic parameter for any drug, the high speed of tubulin polymerization induced by epothilones and their analogs makes the measurement of this end point diYcult. The rate of change in the proportion of polymerized tubulin is, therefore, a more accurate determinant of potency. In order to evaluate tubulinpolymerizing activity, spectrophotometric analyses of turbidity following addition of each drug to a solution of tubulin were performed as previously described [34] . EVective concentration (EC 0.01 ) was deWned as the interpolated concentration capable of inducing an initial slope of 0.01 A280 nm/min rate, and was calculated using the formula: EC 0.01 = concentration/slope. EC 0.01 values obtained for the 15 analogs ranged from 1.0 to 611 M. Ixabepilone displayed potent tubulin-polymerizing activity, with an EC 0.01 value of just 2.0 M. This is consistent with the potent cytotoxicity of ixabepilone as demonstrated by its low IC 50 . However, like IC 50 , EC 0.01 was not a signiWcant predictor of in vivo eYcacy as measured by LCK (r = 0.009; P = 0.97).
Metabolic stability of ixabepilone
As mentioned above, poor metabolic stability of natural epothilone B was one major reason why its promising preclinical antitumor activity did not translate into preclinical in vivo eYcacy. Although human plasma does not contain esterases (unlike mouse plasma), esterases in human liver would, nevertheless, be able to degrade epothilones. It was, therefore, important to establish the metabolic stabilities of the natural epothilones and the 15 analogs in order to select those with the greatest stability in mice, particularly in light of the fact that in vitro activity did not appear to be predictive of in vivo activity.
Metabolic stability was assessed by incubating each drug with mouse S9 liver fraction, obtained by standard methods [35] at 37°C and sampling at 1, 15, and 45 min. Metabolic stability was expressed as the rate of hydrolysis. The results showed that the metabolic stability of the epothilone analogs tested ranged from 0.01 to 1.75 nmol/(min mg protein). Importantly, those analogs susceptible to metabolic breakdown were ineVective in terms of antitumor activity; a Pearson correlation showed that reduced metabolic stability was a signiWcant predictor of poor in vivo antitumor eYcacy as measured by LCK ( Fig. 3a ; r = 0.76; P < 0.004). Natural epothilones A and B were signiWcantly degraded, with hydrolysis rates of 0.5 and 1.02 nmol/(min mg), respectively. Ixabepilone, however, showed very high metabolic stability, with a hydrolysis rate of 0.01 nmol/(min mg). Thus, the metabolic stability of ixabepilone was superior to all natural epothilones and analogs tested, with a rate of hydrolysis 100-fold lower than that of its parent compound, epothilone B. Further nonclinical metabolic studies indicate that ixabepilone is metabolized primarily by cytochrome P450 (CYP) 3A4/5 to many metabolites (but no active metabolites had been identiWed). Ixabepilone is neither a CYP inhibitor nor a CYP inducer at clinically relevant concentrations (BMS unpublished data).
Plasma protein binding
Since plasma protein binding is an important determinant of in vivo drug potency (as discussed above) the plasma protein binding characteristics were determined in mouse plasma. BrieXy, after determining non-speciWc binding in blank serum ultraWltrate, serum samples of test compounds were centrifuged to obtain ultraWltrates. The percentage protein binding was determined by measuring the concentrations in serum and ultraWltrate by HPLC-UV assay. Fig. 3 Development of resistance to paclitaxel, but not ixabepilone, in the human ovarian carcinoma xenograft model A2780. The drug resistance induction protocol employed is as follows: mice bearing the A2780 xenografts were treated with maximum-tolerated dose (MTD) regimens of either paclitaxel (36 mg/kg IV, Q2D £ 5) or ixabepilone (10 mg/kg, IV, Q4D £ 3). Treated tumors underwent a typical response pattern of regression followed by regrowth, resulting in tumor responses of 2.4 and 3.5 LCK for paclitaxel and ixabepilone, respectively. A regrown tumor was re-implanted into another group of mice which were then treated again with each drug at their MTDs. This procedure was repeated during the course of over 3 years. For paclitaxel, resistance developed readily with sensitivity decreased by 75% at the end of 1 year (LCK = 0.6). Percentage of free compound was expressed as 100 £ (C Wltrate )/(C serum ). As was the case with low metabolic stability, high plasma protein binding was signiWcantly predictive of poor in vivo eYcacy, as measured by LCK ( Fig. 3b ; r = 0.76; P < 0.0002). Plasma protein binding of the 15 analogs ranged from 57.5 to 99.3%, with natural epothilone B at the upper end of this range, at 92.0%. Importantly, however, the plasma protein binding of ixabepilone was lower than that of natural epothilone B, at 79.4. It should be noted that the degree of binding of the tubulin agents to plasma protein is unrelated to binding potency to the tubulin target itself (e.g. ixabepilone is more potent than paclitaxel in this regard [14] , whereas paclitaxel is more plasma protein bound at 96%).
Multidrug resistance susceptibility
Susceptibility to MDR is an important characteristic that is related not only to drug resistance, but also tolerability in the in vivo setting. To establish the susceptibility of each agent to MDR, IC 50 values against HCT116/VM46 (MDR resistant) and HCT116 (sensitive) colon cancer cell lines were obtained. The ratio of IC 50 values in MDR resistant versus sensitive lines (MDR R/S) was used as an expression of the relative susceptibility of each drug to MDR; smaller ratios represent lower susceptibility to MDR. Multidrug resistance R/S ratios for the 15 analogs ranged from 0.88 to 16.8; ratios for epothilones A and B were 0.82 and 1.48, respectively. Tolerability was evaluated by using diVerent doses of each analog to determine maximum tolerated dose and weight loss. Not unexpectedly, lower relative MDR susceptibility was a signiWcant predictor of reduced in vivo eYcacy, as measured by LCK ( Fig. 3c ; r = 0.77; P < 0.0001). Notably, of all the measures performed, relative MDR susceptibility was most predictive of in vivo eYcacy, suggesting that it is very important to select compounds with a favorable MDR proWle if preclinical results are to be translated to the clinic.
The MDR susceptibility ratios were lower with all the epothilone analogs tested compared with the taxanes paclitaxel and docetaxel [14] , for which the MDR R/S ratio was >100 in a head-to-head comparison. Ixabepilone had an MDR susceptibility ratio of 7.77, which was substantially lower than that of paclitaxel, but slightly higher than that of most of the other epothilone analogs, thus minimizing the chances of gastrointestinal toxicity.
Further preclinical development of ixabepilone
The above measures show that ixabepilone has potent in vivo antitumor eYcacy, robust metabolic stability, low (but not completely absent) susceptibility to MDR, potent tubulin-polymerizing activity and low plasma protein binding. Since three of these features were found to be signiWcant predictors of in vivo eYcacy in mice as measured by LCK, the proWle of ixabepilone described above was encouraging. On this basis, ixabepilone was selected from all of the analogs tested for further development. Therefore, a number of additional in vitro and in vivo evaluations were conducted for this agent.
In these additional studies, ixabepilone was found to have high preclinical antineoplastic activity in a range of tumor cell lines and in vivo xenografts [14, 36] . In agreement with the data presented here, the in vitro activity of ixabepilone matched that of natural epothilone B in terms of cytotoxicity and microtubule-polymerizing ability. Moreover, the in vivo activity of ixabepilone was superior to that of epothilone B, likely due to the higher metabolic stability and lower protein binding of ixabepilone, as described above. Importantly, this in vitro and in vivo activity extended to cell lines and xenograft models displaying acquired resistance to currently available drugs [14, 36] , consistent with the favorable MDR proWle of ixabepilone in the above experiments. Further evaluation of ixabepilone revealed that, whereas taxanes induce apoptosis through upregulation of caspase-9 activity [37] , ixabepilone aVects multiple apoptotic pathways [38] . Ixabepilone results in enhancement of caspase-2 activity [37] and causes tumor suppressor protein p53 to activate the death eVector Bax through induction of expression of the BH3-only protein PUMA [4, 39, 40] . Additionally, a transcription-independent pathway may be involved in Bax activation in response to ixabepilone [41] .
Overcoming drug resistance with ixabepilone
As described above, drug resistance (either intrinsic or acquired) limits the use of cancer chemotherapies such as taxanes and anthracyclines [15] ; in such cases, other treatment options must be found if disease progression is to be prevented. In the case of ixabepilone, therapeutic concentrations of drug are theoretically maintained within tumor cells due to the reduced susceptibility of ixabepilone to MDR-mediated eZux [15] . Moreover, ixabepilone does not readily induce tumor cells to overexpress P-gp or MRP-1 [15] , suggesting that therapy with ixabepilone would not lead to development of resistance to other drug classes. Indeed, passage of the human ovarian carcinoma xenograft A2780 for more than 3 years in the presence of ixabepilone has not resulted in emergence of resistance. In contrast, resistance to paclitaxel had developed in this model within <6 months of continuous paclitaxel exposure (Fig. 3) .
In addition to MDR, expression of III-tubulin is associated with clinical resistance to taxanes [5] [6] [7] [8] . However, the tubulin-binding mode of ixabepilone aVects the microtubule dynamics of multiple -tubulin isoforms, including IIItubulin [8] . Unlike paclitaxel, which does not target III-tubulin containing microtubules, ixabepilone preferentially suppresses dynamic instability of III-tubulin containing microtubules compared with II-tubulin containing microtubules. Preclinical data also suggest that ixabepilone has activity in models resistant to paclitaxel due to expression of mutant -tubulins [14, 42] .
Collectively, these preclinical results suggest that ixabepilone may be clinically active against disease which is already resistant to a number of prior therapies. As such, ixabepilone may represent an important potential therapy for cancer patients who have limited treatment options.
Ixabepilone clinical development and future directions
Following its preclinical assessment and selection for further development, ixabepilone has been evaluated in a large number of clinical trials and has demonstrated promising activity in a broad range of tumor types, including breast cancer, NSCLC, hormone-refractory prostate cancer, renal cancer, advanced pancreatic cancer and relapsed nonHodgkin's lymphoma [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Particularly striking activity had been observed in metastatic breast cancer (MBC) both in the Wrst-line setting and in patients who were refractory to or had developed resistance to multiple classes of standard chemotherapeutic agents, including importantly taxanes (paclitaxel or docetaxel), anthracyclins and capecitabine (Table 2 ). These promising activities were conWrmed in a randomized, multinational, phase III study in 752 patients with metastatic breast cancer that was resistant to and had progressed after prior anthracyclins and taxane therapy [43] . Based on the results of these pivotal trials (Table 2) , the US Food and Drug Administration (FDA) approved ixabepilone for injection (Ixempra™) for the treatment of two breast cancer indications: (1) in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. (2) As monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.
As mentioned above, eYcacy of ixabepilone has also been demonstrated in chemoresistant renal [17, 44] and pancreatic carcinomas [24] and drug-resistant lung cancer [45] . Moreover, clinical trials in breast cancer patients have demonstrated that ixabepilone shows comparable activity in patients with ER¡ PR¡ HER2-negative (triple-negative) tumors [46] , a disease subgroup with a poor prognosis due to the unsuitability of targeted treatment options (such as hormonal therapies and trastuzumab) [47] . In all cases, ixabepilone had an acceptable and manageable safety proWle. Sensory neuropathy, a common side-eVect associated with many current antineoplastics including taxanes, did occur with ixabepilone treatment, but in most cases was mild-to-moderate and generally reversible.
Given that synergy between the targeted agent trastuzumab and a number of chemotherapy agents (such as cisplatin, docetaxel, thiotepa and etoposide) have been demonstrated [48] [49] [50] , it would be a very welcome advance in chemotherapy to demonstrate synergy of targeted agents with antineoplastic agents with lower susceptibility to common tumor resistance mechanisms. Trials are ongoing and planned, therefore, to investigate the eYcacy of ixabepilone in combination with targeted agents, such as trastuzumab [51] and bevacizumab, following promising preclinical results [52, 53] . Additionally, pilot studies in mice suggest that although ixabepilone is very sensitive to pH, its oral administration in a buVering solution results in comparable eYcacy to that seen with intravenous administration. A number of other epothilones are currently in clinical development; a brief overview of these studies is provided in Table 3 .
Conclusions
The epothilones are a promising new class of antineoplastic agents that have the ability to overcome a variety of tumor resistance mechanisms, a limiting factor with currently used chemotherapeutic agents. Ixabepilone, an epothilone B analog, was selected for further development from among other epothilone analogs due to its promising spectrum of preclinical characteristics and predictors of clinical eYcacy. Ixabepilone has demonstrated eYcacy and tolerability across a spectrum of tumor types, including diYcult to treat patients with extremely limited treatment options. Ixabepilone also has the potential for clinically signiWcant activity in combination with a range of other agents, such as trastuzumab and bevacizumab. The process of rational design and selection of ixabepilone has led to eYcacy and safety in the clinical setting, including promising eYcacy in patients with multidrug-resistant disease. [66, 67] ABJ879 (C20-desmethyl-C20-methylsulfanyl-epothilone B)
Currently in Phase I development Unknown Results yet to be published
